IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

03/18/2026

At AD/PD - Advances in Science & Therapy 2026, the IGC Pharma AI team is joining global researchers and innovators in discussions around data integration and research infrastructure in Alzheimer’s disease.

As part of the conference, the team will present a live demonstration of aha™ (Agentic Harmonization Assistant) on Friday at the Alzheimer’s Disease Data Initiative (ADDI) booth.

aha™ is a multimodal harmonization platform designed to integrate tabular and neuroimaging datasets to support scalable, cross-cohort research.

We look forward to engaging with the scientific community throughout the week and continuing conversations on building stronger data foundations for Alzheimer’s research.

03/11/2026

Behind every step forward in Alzheimer’s research is a team of people united by purpose.

Across departments, from research and technology to operations, individuals work side by side, learning from one another, asking important questions, and collaborating with care and intention.

It’s this shared commitment that helps move innovation forward, always with patients and families at the heart of what we do.

03/08/2026

On International Women’s Day, we recognize the women across IGC Pharma whose leadership and expertise contribute to advancing our work every day.

From research and technology to strategy and operations, their perspectives strengthen collaboration, inspire innovation, and help move Alzheimer’s research forward with purpose and care.

Today, we celebrate their impact and the progress made possible through their dedication and leadership.

03/03/2026

The brain doesn’t work alone.

Researchers are learning that gut health may play a role in Alzheimer’s disease, opening new ways of thinking about how the body and brain are connected.

By studying these connections, science continues to deepen our understanding of Alzheimer’s and the many factors involved in this complex disease.

Learn more in our Science Spotlight: https://igcpharma.com/healing-from-within-gut-health-strategies-that-may-slow-alzheimers-progression/

02/27/2026

Utility patent applications have been filed to protect key elements of IGC Pharma’s Agentic Harmonization Assistant (AHA), which is being designed as a structured, multi-stage architecture intended to automate dataset alignment and validation across diverse Alzheimer’s datasets.

Earlier this year, AHA advanced to the semi-final round of a competitive AI research evaluation program. The Company plans to present additional details regarding AHA’s development roadmap at the upcoming ADPD conference.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-files-utility-patent-133000755.html

02/26/2026

IGC Pharma announced that Ascendiant Capital Markets has issued an updated equity research report covering the Company. According to Ascendiant Capital Markets, the report raises its price target to $5.00 per share.

All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.

A copy of the updated report can be obtained directly from Ascendiant Capital Markets:https://cdn.aelieve.com/04c1e37f-igc-2026.02.23-q3-fy26-preview-fireside-chat.pdf

02/25/2026

Ascendiant Capital Markets has issued an updated equity research report covering IGC Pharma, raising its price target to $5.00 per share.

All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. By referring to these analysts or distributing their opinions, IGC does not commit itself to the validity of such information, conclusions, or recommendations.

Read the full report:https://cdn.aelieve.com/04c1e37f-igc-2026.02.23-q3-fy26-preview-fireside-chat.pdf

02/24/2026

Ascendiant Capital Markets has issued an updated equity research report covering IGC Pharma

All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. By referring to these analysts or distributing their opinions, IGC does not commit itself to the validity of such information, conclusions, or recommendations.

Read the full report:https://cdn.aelieve.com/04c1e37f-igc-2026.02.23-q3-fy26-preview-fireside-chat.pdf

02/24/2026

The Phase 2 CALMA clinical trial of IGC Pharma, evaluating IGC-AD1 for agitation associated with Alzheimer’s disease, continues to expand with the addition of Visionary Investigators Network (VIN) as a clinical research site.

VIN’s Coconut Grove location in Miami, Florida, is led by Dr. Andrew Lerman and supported by experienced research staff. The practice-integrated model supports enrollment capacity, with approximately 70% of planned enrollment completed.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-adds-visionary-investigators-133000014.html

02/20/2026

In Alzheimer’s, progress is shaped not only by science, but also by the people who stand beside their loved ones every day, offering patience, stability, and support through change.

On National Caregiver Day, we recognize their presence and the important role they play in the Alzheimer’s journey, while continuing our commitment to advancing science with empathy and responsibility.

02/18/2026

A Notice of Allowance has been issued by the Canadian Intellectual Property Office covering the proprietary composition underlying IGC-AD1.

Patent Application No. 3,095,729, titled “Method and Composition for Treating CNS Disorders,” secures composition protection across key North American jurisdictions. Approximately 70% of planned enrollment in the Phase 2 CALMA trial has been completed. The Company believes that strengthening composition protection at this stage enhances both the durability and commercial positioning of IGC-AD1 as the program advances.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-secures-north-american-133000184.html

02/18/2026

Today at 1:00 p.m. ET, IGC Pharma’s CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets.

Topics will include Phase 2 CALMA trial updates and advancements across the Company’s broader pipeline of disease-modifying Alzheimer’s candidates.

Register to attend: https://pr.report/ime7

Address

Potomac, MD

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.